کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2115692 | 1546704 | 2006 | 9 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Differentiation and growth inhibition mediated via the RXR:PPARγ heterodimer in colon cancer Differentiation and growth inhibition mediated via the RXR:PPARγ heterodimer in colon cancer](/preview/png/2115692.png)
This study evaluated the anti-tumor efficacy of combining the RXR agonist, bexarotene, with the PPARγ agonist, rosiglitazone, in colon cancer. Moser, a human colon cancer cell line, was treated with bexarotene and rosiglitazone alone or in combination and the effect on growth and differentiation were examined. The data demonstrated that the bexarotene/rosiglitazone combination produced greater efficacy in growth inhibition than either single agent. Furthermore, combination treatment acted cooperatively to decrease COX-2 expression and PGE2 synthesis while increasing expression of the differentiation marker, CEA. These findings were confirmed in vivo in a Moser xenograft tumor model. Collectively, our data suggest a potential role for utilizing a combination regimen of a RXR and PPARγ agonist in the treatment of colon cancer.
Journal: Cancer Letters - Volume 240, Issue 2, 28 August 2006, Pages 225–233